Torrent Pharmaceuticals audited FY26 results; recommends ₹9 final dividend
Torrent Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Audited standalone and consolidated results for the quarter and year ended March 31, 2026 approved by the Board; auditor's opinion unmodified.
- Board recommended a final dividend of ₹9/- (180%) per equity share of ₹5 each, record date May 29, 2026; interim dividend of ₹29/- (580%) paid earlier.
- Incremental qualified borrowings Nil in FY 2025-26; outstanding qualified borrowings Rs. 1605 crores (April 1, 2025) and Rs. 934 crores (March 31, 2026); highest prior-year ratings ICRA AA+(Stable) and IND AA+ (Stable).
Why it's rated major development: the year-on-year change is 27% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Raising of Funds
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Torrent Pharmaceuticals
- Fundraise / allotmentNotableTorrent Pharmaceuticals allotted 4.19 crore shares to JB Chemicals shareholders on amalgamation
- Acquisition / mergerNotableTorrent Pharmaceuticals completes amalgamation with J. B. Chemicals & Pharmaceuticals
- Acquisition / mergerNotableTorrent Pharmaceuticals receives NCLT order approving J.B. Chemicals merger
- Acquisition / mergerNotableTorrent Pharmaceuticals' Scheme of Amalgamation with J. B. Chemicals sanctioned by NCLT
- Fundraise / allotmentMajor development· Adverse for the businessTorrent Pharmaceuticals reports audited Q4 and FY26 results, recommends dividend and QIP
Other fundraise / allotment filings this fortnight
- Supreme Engineering allots 14,50,00,000 warrants at ₹2.60 on preferential basis
- Bajaj Finance Limited allots 5.74 crore warrants to Bajaj Finserv on 10 Nov 2026
- Bajaj Finance approves preferential issue of 5.74 crore warrants to Bajaj Finserv
- Chaman Metallics Limited announces H1 FY27 financial results and proposed Rights Issue
- Harmony Capital Services receives BSE approval for preferential issue of shares
- Kuber Udyog: open offer corrigendum, allotments of shares and warrants at ₹23.10
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.